argenx

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Established: 2008-01-01

Employees: -

Market Cap: $31.2B

Website: https://www.argenx.com/

Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Phase 3

Active, not recruiting

Conditions: Primary Immune Thrombocytopenia

Interventions: Biological: efgartigimod

First Posted Date: 2020-01-13

Last Posted Date: 2024-06-26

Lead Sponsor: argenx

Target Recruit Count: 101

Registration Number: NCT04225156

Locations: 🇭🇺
Investigator Site 0360015, Győr, Hungary
🇮🇹
Investigator Site 0390009, Siena, Italy
🇮🇹
Investigator Site 0390016, Trieste, Italy

and more 84 locations

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).

Phase 3

Completed

Conditions: Primary Immune Thrombocytopenia

Interventions: Other: Placebo
Biological: efgartigimod

First Posted Date: 2019-12-05

Last Posted Date: 2024-03-07

Lead Sponsor: argenx

Target Recruit Count: 131

Registration Number: NCT04188379

Locations: 🇺🇸
Investigator Site 0010040, Columbus, Ohio, United States
🇬🇪
Investigator Site 9950008, Tbilisi, Georgia
🇵🇱
Investigator Site 0480008, Katowice, Poland

and more 118 locations

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: ARGX-113 with rHuPH20

First Posted Date: 2019-08-29

Last Posted Date: 2019-12-30

Lead Sponsor: argenx

Target Recruit Count: 33

Registration Number: NCT04073589

Locations: 🇳🇱
Investigator Site, Groningen, Netherlands

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness.

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Biological: ARGX-113

First Posted Date: 2018-12-10

Last Posted Date: 2023-07-14

Lead Sponsor: argenx

Target Recruit Count: 151

Registration Number: NCT03770403

Locations: 🇺🇸
Investigator Site 8, Los Angeles, California, United States
🇨🇿
Investigator Site 16, Brno, Czechia
🇫🇷
Investigator Site 51, Marseille, France

and more 49 locations

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase 3

Completed

Conditions: Generalized Myasthenia Gravis

Interventions: Biological: Placebo
Biological: ARGX-113

First Posted Date: 2018-09-13

Last Posted Date: 2022-02-08

Lead Sponsor: argenx

Target Recruit Count: 167

Registration Number: NCT03669588

Locations: 🇧🇪
Investigator Site 8, Ghent, Belgium
🇵🇱
Investigator Site 57, Katowice, Poland
🇯🇵
Investigator Site 41, Minato-Ku, Tokyo, Japan

and more 63 locations

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Biological: ARGX-113
Biological: Placebo

First Posted Date: 2018-03-07

Last Posted Date: 2024-05-23

Lead Sponsor: argenx

Target Recruit Count: 62

Registration Number: NCT03457649

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Phase 1

Completed

Conditions: Bioavailability Study

Interventions: Drug: ARGX-113

First Posted Date: 2017-11-07

Last Posted Date: 2020-08-31

Lead Sponsor: argenx

Target Recruit Count: 40

Registration Number: NCT03334084

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Phase 2

Completed

Conditions: Pemphigus Vulgaris
Pemphigus Foliaceus

Interventions: Drug: ARGX-113

First Posted Date: 2017-11-07

Last Posted Date: 2020-12-14

Lead Sponsor: argenx

Target Recruit Count: 34

Registration Number: NCT03334058

Locations: 🇭🇺
University of Pécs Clinical Center , Department of Dermatology, Venerology and Oncodermatology, Pécs, Hungary
🇭🇺
University of Szeged Faculty of Medicine Albert Szent-Györgyi Medical Center Department of Dermatology and Allergology, Szeged, Hungary
🇮🇱
HaEmek Medical center, Dermatology Department, 'Afula, Israel

and more 9 locations

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Phase 2

Completed

Conditions: Primary Immune Thrombocytopenia

Interventions: Other: Placebo
Drug: ARGX-113

First Posted Date: 2017-04-06

Last Posted Date: 2023-07-25

Lead Sponsor: argenx

Target Recruit Count: 38

Registration Number: NCT03102593

Locations: 🇭🇺
Gyula, Gyula, Hungary
🇦🇹
Vienna, Vienna, Austria
🇫🇷
Paris, Paris, France

and more 27 locations

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Phase 2

Completed

Conditions: Myasthenia Gravis

Interventions: Drug: Placebo
Biological: ARGX-113

First Posted Date: 2016-11-17

Last Posted Date: 2024-08-28

Lead Sponsor: argenx

Target Recruit Count: 24

Registration Number: NCT02965573

Locations: 🇺🇸
Investigator Site 19, Irvine, California, United States
🇺🇸
Investigator Site 17, Los Angeles, California, United States
🇺🇸
Investigator Site 16, Indianapolis, Indiana, United States

and more 16 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy